• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, August 8, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Bayesian framework integrates longitudinal EHR data with genetic discovery

Bioengineer by Bioengineer
July 16, 2026
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A new Bayesian system called ALADYNOULLI is designed to forecast how multiple diseases unfold over time from longitudinal electronic health record (EHR) histories. The work targets a central challenge in longitudinal modelling: evaluating prediction without “information leakage,” so that future diagnoses never influence training for past timepoints. By explicitly simulating real clinical follow-up, the researchers aim to make risk estimates more trustworthy for decision-making.

In the primary assessment, ALADYNOULLI produced dynamic 1-year forecasts at 10 fixed moments during follow-up, starting at enrollment and extending to years 1 through 9. At each timepoint, models were retrained using only data available up to that moment, then tested on 1-year outcomes. The key metric was the median area under the receiver operating characteristic curve (AUC) across these dynamic evaluations, summarizing how predictive accuracy changes as new diagnoses accumulate.

The study spans 28 diseases and reports robust discrimination for several clinically important endpoints. Performance was strong for atherosclerotic cardiovascular disease (ASCVD), breast cancer, atrial fibrillation, heart failure, and Parkinson’s disease, with AUC values of 0.879, 0.867, 0.801, 0.811, and 0.796, respectively. Importantly, the evaluation excluded people with prevalent disease at prediction time, aligning the comparisons with prospective risk.

ALADYNOULLI was also benchmarked against established clinical risk tools where feasible. At enrollment, static models trained only on baseline information were compared for both 1-year and 10-year horizons. While longer-term predictions naturally degraded, ALADYNOULLI retained meaningful power—for example, for ASCVD at 10 years—highlighting the advantage of learning from longitudinal EHR trajectories rather than relying solely on cross-sectional inputs.

Calibration analyses further supported reliability: predicted and observed event rates matched closely across millions of at-risk patient-time observations. The researchers report a mean squared error on calibration of 4.67 × 10⁻⁷, with mean predicted rates (5.55 × 10⁻⁴) closely tracking mean observed rates (5.45 × 10⁻⁴). This suggests not only ranking accuracy, but also quantitative risk realism.

To test whether results were driven by subtle temporal artifacts, the team ran sensitivity analyses that excluded events occurring shortly before prediction and varied washout windows. They also examined alternative horizons and a dynamic 10-year rolling interpolation strategy, which updates risk estimates as annual information becomes available. Together, these checks help confirm that temporal patterns are being learned in a causally aligned manner.

Overall, the findings position ALADYNOULLI as a clinically relevant framework for multi-disease risk forecasting, combining longitudinal EHR modelling with predictive discrimination and calibration. By rigorously preventing leakage and validating dynamic follow-up scenarios, the approach offers a pathway toward more actionable, time-aware risk prediction in real-world healthcare settings.

Subject of Research: Longitudinal EHR-based multi-disease risk prediction using Bayesian modelling and genetic/EHR integration
Article Title: A Bayesian framework for longitudinal EHR and genetic discovery.
Article References: Urbut, S.M., Ding, Y., Nakao, T. et al. A Bayesian framework for longitudinal EHR and genetic discovery. Nature (2026). https://doi.org/10.1038/s41586-026-10780-5
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41586-026-10780-5
Keywords: longitudinal EHR, Bayesian framework, disease risk prediction, dynamic forecasting, temporal validation, calibration, AUC, ASCVD

Tags: avoiding information leakage in predictive modelingBayesian framework for healthcare analyticsBayesian longitudinal EHR modelingclinical outcome forecasting over timedisease progression forecastingdisease-specific predictive performance metricsdynamic disease risk estimationelectronic health record data integrationgenetic discovery in disease predictionprevention and early diagnosis of chronic diseasesreal-time clinical risk predictionrobust assessment of disease prediction models

Share12Tweet7Share2ShareShareShare1

Related Posts

Multi-population GWAS maps bladder cancer loci and smoking-related genetic risk

August 8, 2026

Scientists map signaling networks driving disseminated glioblastoma cells in living brains

August 8, 2026

Engineered nanovesicles targeting m6A writer METTL3 curb neuroinflammation in cells and animals

August 8, 2026

ESM1-Mediated DNMT3A Suppresses Cervical Cancer Metastasis via ID3 Epigenetic Regulation

August 8, 2026

POPULAR NEWS

  • Multi-population GWAS maps bladder cancer loci and smoking-related genetic risk

    29 shares
    Share 12 Tweet 7
  • Scientists map signaling networks driving disseminated glioblastoma cells in living brains

    29 shares
    Share 12 Tweet 7
  • Engineered nanovesicles targeting m6A writer METTL3 curb neuroinflammation in cells and animals

    29 shares
    Share 12 Tweet 7
  • Hebrew University Congratulates Haim Sompolinsky on Receiving 2026 Dirac Medal

    29 shares
    Share 12 Tweet 7

About

BIOENGINEER.ORG

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Multi-population GWAS maps bladder cancer loci and smoking-related genetic risk

Scientists map signaling networks driving disseminated glioblastoma cells in living brains

Engineered nanovesicles targeting m6A writer METTL3 curb neuroinflammation in cells and animals

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 86 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.